Belzutifan Safety Profile and Patient Selection in Practice in Advanced RCC

This portion of the discussion focuses specifically on belzutifan related adverse events and how clinicians manage them in practice. Anemia and hypoxia are identified as the most characteristic toxicities associated with HIF-2 inhibition. Fatigue is frequently observed, often related to anemia but sometimes multifactorial.

Patient selection is emphasized as central to safe use. Panelists discuss evaluating pulmonary reserve prior to initiating therapy, particularly in patients with underlying COPD, pleural involvement, prior lung disease, or borderline baseline oxygen saturation. Obstructive sleep apnea is highlighted as an underrecognized contributor to oxygen desaturation, and clinicians describe using home pulse oximetry, including overnight monitoring, to better understand true oxygen trends.

Importantly, although hypoxia may appear concerning numerically, it is often less symptomatic than expected and typically improves with temporary treatment interruption. Education and early recognition are key components of management.

The overall message is that belzutifan can be integrated safely when clinicians anticipate these toxicities, select patients thoughtfully, and monitor proactively.